Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?-Reference-Cited by-同舟云学术

Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?

Published:2020-05 Issue:5 Volume:41 Page:416-425
ISSN:0143-3636
Container-title:Nuclear Medicine Communications
language:en
Short-container-title:Nuclear Medicine Communications

Author:

Makboul Rania,Mostafa Nadia M.,El-Deek Heba E.M.,Aboulhagag Noha A.,Shehata Mahmoud R.,Abdelhafez Yasser G.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Reference46 articles.

1. Thyroid Cancer Epidemiology and Prognostic Variables

2. Prognosis of Differentiated Thyroid Cancer in Relation to Serum Thyrotropin and Thyroglobulin Antibody Status at Time of Diagnosis

3. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer

4. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

5. Recent Developments in the Pathology of Thyroid Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases;Frontiers in Endocrinology;2022-11-02

2. Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma;Molecular and Clinical Oncology;2021-12-23